Semaglutide

Common questions about Semaglutide

What is semaglutide?

Semaglutide is a long-acting GLP-1 receptor agonist studied for glycemic control and weight loss. It is approved as a prescription drug under the brand names Ozempic and Wegovy in many jurisdictions; research-peptide vendors supply the unbranded compound for laboratory use.

Is semaglutide FDA-approved?

Yes — under the brand names Ozempic (for type-2 diabetes) and Wegovy (for chronic weight management). The unbranded research-grade compound sold by peptide vendors is not the FDA-approved finished product and is intended for research use only.

What is the half-life of semaglutide?

Published pharmacokinetic studies report a terminal half-life of approximately 7 days (around 165–184 hours), which supports its once-weekly clinical dosing schedule.

What dose of semaglutide is used in research?

Clinical dosing typically follows a graduated escalation protocol over several weeks. Pepticker does not publish a dosing recommendation — this is a prescription drug when used clinically. Refer to the prescribing information or peer-reviewed studies for the specific protocol you are reproducing.

How is semaglutide different from tirzepatide?

Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual agonist that activates both GLP-1 and GIP receptors. Head-to-head trials have generally reported larger weight-loss outcomes for tirzepatide.

Is semaglutide legal to buy as a research compound?

In the US, Canada, and the UK research-chemical vendors supply the unbranded compound for laboratory use; clinical use requires a prescription. In Australia it is TGA Schedule 4 and prescription-only when used clinically. Status is informational — not legal advice.

Editorial summary of published research. Not medical advice. See /methodology for sourcing.